{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:54:30Z","timestamp":1793318070927,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Current radiological assessments of<jats:sup>18<\/jats:sup>fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging data in diffuse large B-cell lymphoma (DLBCL) can be time consuming, do not yield real-time information regarding disease burden and organ involvement, and hinder the use of FDG-PET to potentially limit the reliance on invasive procedures (e.g. bone marrow biopsy) for risk assessment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Our aim is to enable real-time assessment of imaging-based risk factors at a large scale and we propose a fully automatic artificial intelligence (AI)-based tool to rapidly extract FDG-PET imaging metrics in DLBCL. On availability of a scan, in combination with clinical data, our approach generates clinically informative risk scores with minimal resource requirements. Overall, 1268 patients with previously untreated DLBCL from the phase III GOYA trial (NCT01287741) were included in the analysis (training:<jats:italic>n<\/jats:italic>\u2009=\u2009846; hold-out:<jats:italic>n<\/jats:italic>\u2009=\u2009422).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our AI-based model comprising imaging and clinical variables yielded a tangible prognostic improvement compared to clinical models without imaging metrics. We observed a risk increase for progression-free survival (PFS) with hazard ratios [HR] of 1.87 (95% CI: 1.31\u20132.67) vs 1.38 (95% CI: 0.98\u20131.96) (C-index: 0.59 vs 0.55), and a risk increase for overall survival (OS) (HR: 2.16 (95% CI: 1.37\u20133.40) vs 1.40 (95% CI: 0.90\u20132.17); C-index: 0.59 vs 0.55). The combined model defined a high-risk population with 35% and 42% increased odds of a 4-year PFS and OS event, respectively, versus the International Prognostic Index components alone. The method also identified a subpopulation with a 2-year Central Nervous System (CNS)-relapse probability of 17.1%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our tool enables an enhanced risk stratification compared with IPI, and the results indicate that imaging can be used to improve the prediction of central nervous system relapse in DLBCL. These findings support integration of clinically informative AI-generated imaging metrics into clinical workflows to improve identification of high-risk DLBCL patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>Registered clinicaltrials.gov number: NCT01287741.<\/jats:p><\/jats:sec><jats:sec><jats:title>Graphical Abstract<\/jats:title><\/jats:sec>","DOI":"10.1186\/s40644-022-00476-0","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T08:08:56Z","timestamp":1660291736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Full automation of total metabolic tumor volume from FDG-PET\/CT in DLBCL for baseline risk assessments"],"prefix":"10.1186","volume":"22","author":[{"given":"S.","family":"Jemaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. N.","family":"Paulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hutchings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kostakoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Trotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tracy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"de Crespigny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A. D.","family":"Carano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. C.","family":"El-Galaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. G.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9667-8873","authenticated-orcid":false,"given":"T.","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"issue":"1","key":"476_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","volume":"50","author":"S Li","year":"2018","unstructured":"Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74\u201387.","journal-title":"Pathology"},{"issue":"5","key":"476_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1470-2045(19)30021-X","volume":"20","author":"F Jardin","year":"2019","unstructured":"Jardin F. Improving R-CHOP in diffuse large B-cell lymphoma is still a challenge. Lancet Oncol. 2019;20(5):605\u20136.","journal-title":"Lancet Oncol"},{"issue":"4","key":"476_CR3","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1073\/pnas.1205299110","volume":"110","author":"J Zhang","year":"2013","unstructured":"Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013;110(4):1398\u2013403.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"476_CR4","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","volume":"2016","author":"B Coiffier","year":"2016","unstructured":"Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematology Am Soc Hematol Educ Program. 2016;2016(1):366\u201378.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"476_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/bmt.2015.213","volume":"51","author":"E Van Den Neste","year":"2016","unstructured":"Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016;51(1):51\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"476_CR6","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20138.","journal-title":"Blood"},{"key":"476_CR7","doi-asserted-by":"publisher","unstructured":"Frederick L. Locke, M.D., David B. Miklos, M.D., Ph.D., Caron A. Jacobson, M.D., et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med 2022. 386:640\u2013654 https:\/\/doi.org\/10.1056\/NEJMoa2116133","DOI":"10.1056\/NEJMoa2116133"},{"key":"476_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, M.D., Michael R. Bishop, M.D., Constantine S. Tam, M.D., et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380:45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980.","journal-title":"N Engl J Med"},{"issue":"5","key":"476_CR9","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857\u201361.","journal-title":"Blood"},{"issue":"11","key":"476_CR10","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/ajh.24169","volume":"90","author":"TC El-Galaly","year":"2015","unstructured":"El-Galaly TC, Villa D, Alzahrani M, et al. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET\/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. Am J Hematol. 2015;90(11):1041\u20136.","journal-title":"Am J Hematol"},{"issue":"6","key":"476_CR11","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837\u201342.","journal-title":"Blood"},{"key":"476_CR12","doi-asserted-by":"publisher","unstructured":"Kostakoglu L, Mattiello F, Martelli M, Sehn LH, Belada D, Ghiggi C, Chua N, Gonz\u00e1lez-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Bolen C, Knapp A, Sellam G, Nielsen T, Sahin D, Vitolo U, Trn\u011bn\u00fd M. Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study. Haematologica; https:\/\/doi.org\/10.3324\/haematol.2021.278663.","DOI":"10.3324\/haematol.2021.278663"},{"issue":"8","key":"476_CR13","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1158\/1078-0432.CCR-04-2626","volume":"11","author":"GJ Kelloff","year":"2005","unstructured":"Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005;11(8):2785\u2013808.","journal-title":"Clin Cancer Res"},{"key":"476_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40644-016-0091-3","volume":"16","author":"MS Hofman","year":"2016","unstructured":"Hofman MS, Hicks RJ. How We Read Oncologic FDG PET\/CT. Cancer Imaging. 2016;16:35. https:\/\/doi.org\/10.1186\/s40644-016-0091-3.","journal-title":"Cancer Imaging"},{"key":"476_CR15","doi-asserted-by":"publisher","unstructured":"Meignan, M. FDG-PET in lymphoma. cancer imaging 14, O23 (2014) https:\/\/doi.org\/10.1186\/1470-7330-14-S1-O23","DOI":"10.1186\/1470-7330-14-S1-O23"},{"issue":"2","key":"476_CR16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1148\/radiol.12111148","volume":"264","author":"HH Chen","year":"2012","unstructured":"Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET\/CT in non-small cell lung cancer. Radiology. 2012;264(2):559\u201366.","journal-title":"Radiology"},{"key":"476_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40644-014-0034-9","volume":"14","author":"M Coughlan","year":"2014","unstructured":"Coughlan M, Elstrom R. The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy. Cancer Imaging. 2014;14:34. https:\/\/doi.org\/10.1186\/s40644-014-0034-9.","journal-title":"Cancer Imaging"},{"issue":"7","key":"476_CR18","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","volume":"43","author":"NG Mikhaeel","year":"2016","unstructured":"Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43(7):1209\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"476_CR19","doi-asserted-by":"publisher","unstructured":"N. George Mikhaeel, MD ; Martijn W. Heymans, PhD ; Jakoba J. Eertink, PhD, et al. Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index. J Clin Onc. 2022 https:\/\/doi.org\/10.1200\/JCO.21.02063","DOI":"10.1200\/JCO.21.02063"},{"issue":"4","key":"476_CR20","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/s10278-020-00341-1","volume":"33","author":"S Jemaa","year":"2020","unstructured":"Jemaa S, Fredrickson J, Carano RAD, Nielsen T, de Crespigny A, Bengtsson T. Tumor segmentation and feature extraction from whole-body FDG-PET\/CT using cascaded 2D and 3D convolutional neural networks. J Digit Imaging. 2020;33(4):888\u201394.","journal-title":"J Digit Imaging"},{"issue":"1","key":"476_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2967\/jnumed.120.242412","volume":"62","author":"N Capobianco","year":"2021","unstructured":"Capobianco N, Meignan M, Cottereau A-S, Vercellino L, Sibille L, Spottiswoode B, Zuehlsdorff S, Casasnovas O, Thieblemont C, Buvat I. Deep-learning 18F-FDG uptake classification enables total metabolic tumor volume estimation in diffuse large B-cell lymphoma. J Nucl Med. 2021;62(1):30\u20136.","journal-title":"J Nucl Med"},{"key":"476_CR22","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1007\/s00259-020-05080-7","volume":"48","author":"P Blanc-Durand","year":"2021","unstructured":"Blanc-Durand P, J\u00e9gou S, Kanoun S, Berriolo-Riedinger A, Bodet-Milin C, Kraeber-Bod\u00e9r\u00e9 F, Carlier T, Le Gouill S, Casasnovas RO, Meignan M, Itti E. Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET\/CT for total metabolic tumour volume prediction using a convolutional neural network. Eur J Nucl Med Mol Imaging. 2021;48:1362\u201370.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"476_CR23","doi-asserted-by":"crossref","DOI":"10.1148\/ryai.2020200016","volume":"2","author":"AJ Weisman","year":"2020","unstructured":"Weisman AJ, Kieler MW, Perlman SB, Hutchings M, Jeraj R, Kostakoglu L, Bradshaw TJ. Convolutional neural networks for automated PET\/CT detection of diseased lymph node burden in patients with lymphoma. Radiol Artif Intell. 2020;2: e20001.","journal-title":"Radiol Artif Intell"},{"issue":"31","key":"476_CR24","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","volume":"35","author":"U Vitolo","year":"2017","unstructured":"Vitolo U, Trneny M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3529\u201337.","journal-title":"J Clin Oncol"},{"issue":"1","key":"476_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-020-00900-7","volume":"13","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Martelli M, Trn\u011bn\u00fd M, et al. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. J Hematol Oncol. 2020;13(1):71.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"476_CR26","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ajh.25493","volume":"94","author":"F St-Pierre","year":"2019","unstructured":"St-Pierre F, Broski SM, LaPlant BR, et al. Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma. Am J Hematol. 2019;94(7):786\u201393.","journal-title":"Am J Hematol"},{"issue":"10","key":"476_CR27","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.2967\/jnumed.113.134486","volume":"55","author":"JJ Cerci","year":"2014","unstructured":"Cerci JJ, Gy\u00f6rke T, Fanti S, et al. Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma. J Nucl Med. 2014;55(10):1591\u20137.","journal-title":"J Nucl Med"},{"issue":"9","key":"476_CR28","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1182\/blood-2018-07-862862","volume":"133","author":"M Klanova","year":"2019","unstructured":"Klanova M, Sehn LH, Bence-Bruckler I, et al. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood. 2019;133(9):919\u201326.","journal-title":"Blood"},{"issue":"5","key":"476_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v039.i05","volume":"39","author":"N Simon","year":"2011","unstructured":"Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for Cox\u2019s proportional hazards model via coordinate descent. J Stat Softw. 2011;39(5):1\u201313.","journal-title":"J Stat Softw"},{"key":"476_CR30","unstructured":"Therneau TM. 2020. A Package for Survival Analysis in R. R package version 3.2\u20137. Available at: https:\/\/cran.r-project.org\/web\/packages\/survival\/index.html. Accessed April 2021."},{"key":"476_CR31","unstructured":"Stanley E. 2020. HEOR: Examining the effectiveness, costs of various DLBCL treatments. First Report Managed Care. Available at: https:\/\/www.managedhealthcareconnect.com\/articles\/heor-examining-effectiveness-costs-various-dlbcl-treatments. Accessed April 2021."},{"issue":"16","key":"476_CR32","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1182\/blood.2019003526","volume":"135","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Cottereau A-S, Casasnovas O, et al. High total metabolic tumor volume at baseline predicts survival independent of response to therapy. Blood. 2020;135(16):1396\u2013405.","journal-title":"Blood"},{"issue":"4","key":"476_CR33","first-page":"469","volume":"55","author":"E Pelosi","year":"2011","unstructured":"Pelosi E, Penna D, Douroukas A, et al. Bone marrow disease detection with FDG-PET\/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study. Q J Nucl Med Mol Imaging. 2011;55(4):469\u201375.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"8","key":"476_CR34","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.2967\/jnumed.112.114710","volume":"54","author":"L Berthet","year":"2013","unstructured":"Berthet L, Cochet A, Kanoun S, et al. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET\/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med. 2013;54(8):1244\u201350.","journal-title":"J Nucl Med"},{"issue":"1","key":"476_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood-2012-12-473389","volume":"122","author":"AB Khan","year":"2013","unstructured":"Khan AB, Barrington SF, Mikhaeel NG, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood. 2013;122(1):61\u20137.","journal-title":"Blood"},{"issue":"6","key":"476_CR36","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1093\/annonc\/mdw137","volume":"27","author":"M Alzahrani","year":"2016","unstructured":"Alzahrani M, El-Galaly TC, Hutchings M, et al. The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET\/CT: a Danish-Canadian study. Ann Oncol. 2016;27(6):1095\u20139.","journal-title":"Ann Oncol"},{"issue":"1","key":"476_CR37","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13550-020-00698-y","volume":"10","author":"C Jiang","year":"2020","unstructured":"Jiang C, Teng Y, Chen J, et al. Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL). EJNMMI Res. 2020;10(1):110.","journal-title":"EJNMMI Res"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-022-00476-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-022-00476-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-022-00476-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T15:07:10Z","timestamp":1700924830000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-022-00476-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["476"],"URL":"https:\/\/doi.org\/10.1186\/s40644-022-00476-0","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"assertion":[{"value":"9 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study analyzed data from the randomized phase III GOYA trial (NCT01287741). The trial was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization of Good Clinical Practice guidelines. Trial protocol approval was obtained from the ethics committee\/institutional review board at each participating institution and written informed consent to participate was provided by all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.J and J.N.P are employees of Genentech, Inc. and stockholders of F. Hoffmann-La Roche Ltd. M.H reports no conflicts of interest. L.K is a consultant for F. Hoffmann-La Roche Ltd and Genentech, Inc. and reports travel expenses from F. Hoffmann-La Roche Ltd. J.T reports research funding from F. Hoffmann-La Roche Ltd., Celgene, Janssen, PCYC and Beigene. S.T is an employee of Genentech, Inc. and F. Hoffmann-La Roche Ltd and a stockholder of F. Hoffmann-La Roche Ltd. A.D.C and R.A.D.C are employees of Genentech, Inc. and stockholders of F. Hoffmann-La Roche Ltd. T.C.E\u2013G was an employee of F. Hoffmann-La Roche Ltd. T.N is an employee and stockholder of F. Hoffmann-La Roche Ltd. T.B was an employee of Genentech, Inc. at the time of the manuscript completion. No other potential conflicts of interest relevant to this article exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"competing interests"}}],"article-number":"39"}}